Payment overview · 2025
General Payments
$59.83
4 reported records · 3 companies
Healthcare provider profile · identity verified
Shane M Mcvay, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HODGE, LA · NPI 1700222379
Verified facts
What the public records show
CMS Open Payments records show Shane M Mcvay, FNP received $59.83 in general payments during 2025 across 4 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 48.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.89 | 48.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.19 | 28.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.75 | 23.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.83 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 398 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 353 | 81 |
| Gabapentin | Gabapentin | 326 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 315 | 81 |
| Omeprazole | Omeprazole | 228 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 223 | 55 |
| Lisinopril | Lisinopril | 220 | 57 |
| Meloxicam | Meloxicam | 220 | 68 |
| Furosemide | Furosemide | 213 | 52 |
| Sertraline Hcl | Sertraline Hcl | 208 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 54 |
| Losartan Potassium | Losartan Potassium | 169 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 36 |
| Potassium Chloride | Potassium Chloride | 156 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 34 |
| Simvastatin | Simvastatin | 125 | 31 |
| Ozempic | Semaglutide | 118 | 25 |
| Trazodone Hcl | Trazodone Hcl | 117 | 25 |
| Metformin Hcl | Metformin Hcl | 116 | 35 |
| Eliquis | Apixaban | 112 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 27 |
| Jardiance | Empagliflozin | 109 | 19 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 106 | 88 |
| Prednisone | Prednisone | 100 | 64 |
| Atenolol | Atenolol | 92 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 57 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 17 |
| Kerendia | Finerenone | 77 | 15 |
| Azithromycin | Azithromycin | 76 | 70 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Finasteride | Finasteride | 73 | 16 |
| Metformin Hcl Er | Metformin Hcl | 73 | 22 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 73 | suppressed |
| Alprazolam | Alprazolam | 71 | 21 |
| Farxiga | Dapagliflozin Propanediol | 71 | 15 |
| Buspirone Hcl | Buspirone Hcl | 70 | 15 |
| Allopurinol | Allopurinol | 69 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 32 |
| Azelastine Hcl | Azelastine Hcl | 66 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 12 |
| Alendronate Sodium | Alendronate Sodium | 61 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 19 |
| Spironolactone | Spironolactone | 61 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 19 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Carvedilol | Carvedilol | 53 | 11 |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 15 |
| Montelukast Sodium | Montelukast Sodium | 51 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 12 |
| Nifedipine Er | Nifedipine | 49 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 12 |
| Ondansetron Odt | Ondansetron | 47 | 26 |
| Febuxostat | Febuxostat | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 14 |
| Fluconazole | Fluconazole | 45 | 27 |
| Mounjaro | Tirzepatide | 45 | 12 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 45 | 17 |
| Levofloxacin | Levofloxacin | 44 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | 11 |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Lorazepam | Lorazepam | 41 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 20 |
| Chlorthalidone | Chlorthalidone | 39 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 28 |
| Baclofen | Baclofen | 36 | suppressed |
| Famotidine | Famotidine | 36 | 13 |
| Fosinopril Sodium | Fosinopril Sodium | 36 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 16 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Temazepam | Temazepam | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | 15 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 16 |
| Valsartan | Valsartan | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.83 · 4 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Cologuard Collection Kit, JARDIANCE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error